Author

M. O'Sullivan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Arnott· 1 shared A. Swarbrick· 1 shared C. C. Goodnow· 1 shared C. J. Jara· 1 shared C. Lam· 1 shared C. Ma· 1 shared D. E. Dwyer· 1 shared D. Ko· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Arnott

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological dysregulation of NKG2Dhi CD8 killer T cells

E. Masle-Farquhar, K. J. L. Jackson, T. J. Peters, G. Al-Eryani, M. Singh, K. J. Payne, G. Rao, G. Apps, J. Kingham, C. J. Jara, K. Skvortsova, A. Swarbrick, C. Ma, D. Suan, G. Uzel, , C. C. Goodnow

This study shows that STAT3 gain-of-function mutations in leukemia drive autoimmune pathology by causing NKG2Dhi CD8 T cell oligoclonal expansion and cytotoxic activity.

bioRxiv · Feb 11, 2022 · PreprintImmunology

Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting

K. Basile, R. J. Rockett, K. McPhie, M. Fennell, J. Johnson-Mackinnon, J. Agius, W. Fong, H. Rahman, D. Ko, L. Donavan, L. Hueston, C. Lam, A. Arnott, S. Chen, S. Maddocks, , J. Kok

This study shows that Pfizer-BioNTech vaccine boosting increases neutralizing antibodies against Omicron, but they are still lower than against the A.2.2 lineage.

bioRxiv · Dec 12, 2021 · PreprintMicrobiology